Abstract We report here a pharmaceutical cocrystal, which was composed of iloperidone with 3, 5-pyridinedicarboxlic acid by crystal engineering strategy. It was characterized by single crystal X-ray and powder X-ray diffraction, which demonstrated that the cocrystal with high purity was obtained. Pharmacokinetics (PK) study of Jilin University China-Cocrystal 10 (JUC-C10) was performed to evaluate the advantages of this strategy for enhancing the oral absorption of the original active pharmaceutical ingredient (API) of iloperidone. The in vivo study of Beagle dogs revealed that the plasma concentration of JUC-C10 reached the maximum concentration and effective blood level earlier than the original API after oral administration, which suggested that JUC-C10 exhibited a more rapid absorption profile and could thus achieve a rapid onset of action.
The pharmaceutical cocrystals have seen a tremendous increase in the recent 10 years due to the potential physicochemical and biological properties of these materials in such aspects as stability, solubility, dissolution, bioavailability, hygroscopicity and compatibility [1] [2] [3] [4] [5] . These compounds are generally constructed from active pharmaceutical ingredients (APIs) [3, 6, 7] linked by cocrystal formers (CCFs) [2, [8] [9] [10] , which bond to APIs for a synthon via hydrogen bonds or non-covalent bonds [11, 12] . But beyond that, the CCFs were included not only in their potential applications for bonding but also in the pharmaceutically acceptable formers list, such as Generally Regarded as Safe (GRAS) list and Everything Added to Food in the United States (EAFUS) list [13, 14] . In our research, iloperidone, which is a second-generation antipsychotic agent approved by the US Food and Drug Administration (FDA) in 2009 for the treatment of schizophrenia in adults [15] , was selected to exploit its novel crystal forms with excellent physicochemical and biological properties. Moreover, iloperidone is classified as a Class II category (low solubility and high permeability) according to the Biopharmaceutics Classification System (BCS) [16] , which is practically insoluble in water (0.012 mg/mL) [17] [18] .
Oral bioavailability of iloperidone was <1% in rat, 5% in mouse, 19% in both rabbit and dog, and approximately 36% in humans. Based on the description, we employed 3, 5-pyridinedicarboxlic acid to synthesize the cocrystal of iloperidone (Scheme 1). (Table S1) , and the 1D chain links the 2D layer viaπ-πstacking from the dimers to further generate an infinite 3D framework. Theπ-πstacking dimers are arranged along the crystallographic c-axis and the distance is 3.677 Å. In addition, the packing motif is illustrated in head-to-head dimers of the adjacent molecules of iloperidone, and the distance is 3.645 Å. The synthesized PXRD pattern of JUC-C10 exhibits good agreement with the calculated XRPD pattern based on a single crystal structure (Fig. 2) with an enhanced solubility would be potential to favorably affect the gastrointestinal (GI) absorption and onset action of iloperidone.
The single crystal X-ray and powder X-ray diffraction certified that JUC-C10
with high purity was obtained in a mild condition. After confirming the structures, the dissolution and pharmacokinetic studies were conducted to evaluate the pharmaceutical characteristics of original API and JUC-C10. The great improvement of absorption illustrated that JUC-C10 would be a favored candidate for the pharmaceutical industry. In addition, the toxicity and efficacy studies were still underway in our laboratory. 
